Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

vertex pharmaceuticals inc. - VRTX

VRTX

Close Chg Chg %
448.62 6.35 1.42%

Closed Market

454.97

+6.35 (1.42%)

Volume: 1.20M

Last Updated:

Mar 25, 2026, 4:00 PM EDT

Trade Now

Company Overview: vertex pharmaceuticals inc. - VRTX

VRTX Key Data

Open

$450.00

 Day Range

449.14 - 459.37

52 Week Range

362.50 - 510.77

 Market Cap

$113.96B

Shares Outstanding

254.03M

 Public Float

253.20M

Beta

0.31

 Rev. Per Employee

N/A

P/E Ratio

29.28

 EPS

$15.47

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.46M

  

VRTX Performance

1 Week
 
 0.21%
 
1 Month
 
 -8.43%
 
3 Months
 
 -1.71%
 
1 Year
 
 -7.66%
 
5 Years
 
 111.97%
 

VRTX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 36
Full Ratings ➔

About vertex pharmaceuticals inc. - VRTX

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

VRTX At a Glance

Vertex Pharmaceuticals, Inc.
50 Northern Avenue
Boston, Massachusetts 02210
Phone 1-617-341-6100 Revenue 12.07B
Industry Pharmaceuticals: Major Net Income 3.95B
Sector Health Technology 2025 Sales Growth 9.925%
Fiscal Year-end 12 / 2026 Employees 6,400
View SEC Filings

VRTX Valuation

P/E Current 29.279
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 29.588
Price to Sales Ratio 9.687
Price to Book Ratio 6.169
Price to Cash Flow Ratio 32.21
Enterprise Value to EBITDA 22.624
Enterprise Value to Sales 9.308
Total Debt to Enterprise Value 0.018

VRTX Efficiency

Revenue/Employee 1,886,656.25
Income Per Employee 617,687.50
Receivables Turnover 5.882
Total Asset Turnover 0.491

VRTX Liquidity

Current Ratio 2.901
Quick Ratio 2.464
Cash Ratio 1.712

VRTX Profitability

Gross Margin 85.034
Operating Margin 39.427
Pretax Margin 38.454
Net Margin 32.74
Return on Assets 16.059
Return on Equity 22.541
Return on Total Capital 19.096
Return on Invested Capital 20.437

VRTX Capital Structure

Total Debt to Total Equity 10.908
Total Debt to Total Capital 9.835
Total Debt to Total Assets 7.788
Long-Term Debt to Equity 10.464
Long-Term Debt to Total Capital 9.435
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Vertex Pharmaceuticals Inc. - VRTX

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
8.75B 9.84B 10.98B 12.07B
Sales Growth
+15.04% +12.47% +11.64% +9.92%
Cost of Goods Sold (COGS) incl D&A
1.08B 1.26B 1.53B 1.81B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
148.30M 181.30M 205.80M 207.20M
Depreciation
148.30M 167.80M 160.40M 155.80M
Amortization of Intangibles
- 1.70M 20.20M 20.20M
COGS Growth
+19.48% +16.84% +21.26% +18.07%
Gross Income
7.67B 8.58B 9.45B 10.27B
Gross Income Growth
+14.44% +11.85% +10.23% +8.61%
Gross Profit Margin
+87.65% +87.17% +86.07% +85.03%
2022 2023 2024 2025 5-year trend
SG&A Expense
3.48B 4.30B 5.09B 5.51B
Research & Development
2.54B 3.16B 3.63B 3.75B
Other SG&A
944.70M 1.14B 1.46B 1.75B
SGA Growth
-10.44% +23.37% +18.49% +8.09%
Other Operating Expense
- - - -
-
Unusual Expense
230.00M 478.60M 4.63B 560.10M
EBIT after Unusual Expense
3.95B 3.80B (266.40M) 4.20B
Non Operating Income/Expense
321.30M 625.20M 545.50M 455.90M
Non-Operating Interest Income
144.60M 614.70M 598.10M 490.90M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
54.80M 44.10M 30.60M 13.30M
Interest Expense Growth
-10.89% -19.53% -30.61% -56.54%
Gross Interest Expense
54.80M 44.10M 30.60M 13.30M
Interest Capitalized
- - - -
-
Pretax Income
4.23B 4.38B 248.50M 4.64B
Pretax Income Growth
+55.01% +3.48% -94.33% +1,768.49%
Pretax Margin
+48.38% +44.51% +2.26% +38.45%
Income Tax
910.40M 760.20M 784.10M 690.00M
Income Tax - Current - Domestic
813.90M 946.60M 823.10M 715.00M
Income Tax - Current - Foreign
372.40M 350.10M 309.80M 485.80M
Income Tax - Deferred - Domestic
(415.00M) (591.80M) (487.40M) (549.10M)
Income Tax - Deferred - Foreign
139.10M 55.30M 138.60M 38.30M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
3.32B 3.62B (535.60M) 3.95B
Minority Interest Expense
- - - -
-
Net Income
3.32B 3.62B (535.60M) 3.95B
Net Income Growth
+41.84% +8.96% -114.80% +838.09%
Net Margin Growth
+37.97% +36.79% -4.88% +32.74%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
3.32B 3.62B (535.60M) 3.95B
Preferred Dividends
- - - -
-
Net Income Available to Common
3.32B 3.62B (535.60M) 3.95B
EPS (Basic)
12.9715 14.0458 -2.0768 15.4603
EPS (Basic) Growth
+42.72% +8.28% -114.79% +844.43%
Basic Shares Outstanding
256.10M 257.70M 257.90M 255.70M
EPS (Diluted)
12.8213 13.8948 -2.0768 15.3225
EPS (Diluted) Growth
+42.28% +8.37% -114.95% +837.79%
Diluted Shares Outstanding
259.10M 260.50M 257.90M 258.00M
EBITDA
4.33B 4.46B 4.57B 4.97B
EBITDA Growth
+47.59% +2.94% +2.39% +8.82%
EBITDA Margin
+49.51% +45.32% +41.56% +41.14%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 553.607
Number of Ratings 36 Current Quarters Estimate 4.468
FY Report Date 03 / 2026 Current Year's Estimate 19.32
Last Quarter’s Earnings 5.03 Median PE on CY Estimate N/A
Year Ago Earnings 18.40 Next Fiscal Year Estimate 22.253
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 24 23 30 26
Mean Estimate 4.47 4.74 19.32 22.25
High Estimates 5.23 5.32 22.66 27.21
Low Estimate 3.67 4.01 17.49 19.78
Coefficient of Variance 8.12 6.45 5.37 8.77

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 25 22 21
OVERWEIGHT 3 3 2
HOLD 6 6 11
UNDERWEIGHT 2 2 2
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Vertex Pharmaceuticals Inc. - VRTX

Date Name Shares Transaction Value
Mar 18, 2026 Carmen Bozic EVP and CMO 35,405 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $481.79 per share 17,057,774.95
Mar 3, 2026 Kristin Ambrose SVP & Chief Accounting Officer 6,624 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $483.36 per share 3,201,776.64
Feb 20, 2026 Nia Tatsis EVP, Chief Reg. & Quality Off. 49,018 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $489.46 per share 23,992,350.28
Feb 20, 2026 Nia Tatsis EVP, Chief Reg. & Quality Off. 49,627 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $483.75 per share 24,007,061.25
Feb 20, 2026 Nia Tatsis EVP, Chief Reg. & Quality Off. 51,921 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2026 Jonathan Prim Biller EVP and Chief Legal Officer 15,748 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $473.68 per share 7,459,512.64
Feb 20, 2026 Jonathan Prim Biller EVP and Chief Legal Officer 16,992 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $489.46 per share 8,316,904.32
Feb 20, 2026 Jonathan Prim Biller EVP and Chief Legal Officer 19,468 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $483.75 per share 9,417,645.00
Feb 20, 2026 Jonathan Prim Biller EVP and Chief Legal Officer 20,973 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2026 Reshma Kewalramani CEO & President; Director 143,259 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $483.75 per share 69,301,541.25
Feb 20, 2026 Reshma Kewalramani CEO & President; Director 149,813 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2026 Carmen Bozic EVP and CMO 41,516 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $483.75 per share 20,083,365.00
Feb 20, 2026 Charles F. Wagner EVP, CO & FO 51,080 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2026 Amit K. Sachdev EVP Chief Patient & Ext Af Off 69,042 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $483.75 per share 33,399,067.50
Feb 20, 2026 Amit K. Sachdev EVP Chief Patient & Ext Af Off 71,182 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2026 Kristin Ambrose SVP & Chief Accounting Officer 9,945 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $483.75 per share 4,810,893.75
Feb 20, 2026 Duncan J. McKechnie EVP, Chief Commercial Officer 23,342 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $483.75 per share 11,291,692.50
Feb 20, 2026 Nia Tatsis EVP, Chief Reg. & Quality Off. 48,650 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $473.68 per share 23,044,532.00
Feb 20, 2026 Jeffrey M. Leiden Executive Chairman; Director 38,344 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $483.75 per share 18,548,910.00
Feb 20, 2026 Jeffrey M. Leiden Executive Chairman; Director 41,308 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Vertex Pharmaceuticals Inc. in the News